

Anticancer Activities of Six Selected Natural Compounds of Some Cameroonian Medicinal Plants

Victor Kuete^{1,2}, Hippolyte K. Wabo³, Kenneth O. Eyong⁴, Michel T. Feussi³, Benjamin Wiench², Benjamin Krusche², Pierre Tane³, Gabriel N. Folefoc⁴, Thomas Efferth^{2*}

1 Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon, **2** Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Mainz, Germany, **3** Department of Chemistry, Faculty of Science, University of Dschang, Dschang, Cameroon, **4** Department of Organic Chemistry, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon

Abstract

Background: Natural products are well recognized as sources of drugs in several human ailments. In the present work, we carried out a preliminary screening of six natural compounds, xanthone V₁ (1); 2-acetylfuro-1,4-naphthoquinone (2); physcion (3); bisvismiaquinone (4); vismiaquinone (5); 1,8-dihydroxy-3-geranyloxy-6-methylantraquinone (6) against MiaPaCa-2 pancreatic and CCRF-CEM leukemia cells and their multidrug-resistant subline, CEM/ADR5000. Compounds 1 and 2 were then tested in several other cancer cells and their possible mode of action were investigated.

Methodology/Findings: The tested compounds were previously isolated from the Cameroonian medicinal plants *Vismia laurentii* (1, 3, 4, 5 and 6) and *Newbouldia laevis* (2). The preliminary cytotoxicity results allowed the selection of xanthone V₁ and 2-acetylfuro-1,4-naphthoquinone, which were then tested on a panel of cancer cell lines. The study was also extended to the analysis of cell cycle distribution, apoptosis induction, caspase 3/7 activation and the anti-angiogenic properties of xanthone V₁ and 2-acetylfuro-1,4-naphthoquinone. IC₅₀ values around or below 4 µg/ml were obtained on 64.29% and 78.57% of the tested cancer cell lines for xanthone V₁ and 2-acetylfuro-1,4-naphthoquinone, respectively. The most sensitive cell lines (IC₅₀<1 µg/ml) were breast MCF-7 (to xanthone V₁), cervix HeLa and Caski (to xanthone V₁ and 2-acetylfuro-1,4-naphthoquinone), leukemia PF-382 and melanoma colo-38 (to 2-acetylfuro-1,4-naphthoquinone). The two compounds showed respectively, 65.8% and 59.6% inhibition of the growth of blood capillaries on the chorioallantoic membrane of quail eggs in the anti-angiogenic assay. Upon treatment with two fold IC₅₀ and after 72 h, the two compounds induced cell cycle arrest in S-phase, and also significant apoptosis in CCRF-CEM leukemia cells. Caspase 3/7 was activated by xanthone V₁.

Conclusions/Significance: The overall results of the present study provided evidence for the cytotoxicity of compounds xanthone V₁ and 2-acetylfuro-1,4-naphthoquinone, and bring supportive data for future investigations that will lead to their use in cancer therapy.

Citation: Kuete V, Wabo HK, Eyong KO, Feussi MT, Wiench B, et al. (2011) Anticancer Activities of Six Selected Natural Compounds of Some Cameroonian Medicinal Plants. PLoS ONE 6(8): e21762. doi:10.1371/journal.pone.0021762

Editor: Maria A. Deli, Biological Research Center of the Hungarian Academy of Sciences, Hungary

Received: March 23, 2011; **Accepted:** June 6, 2011; **Published:** August 19, 2011

Copyright: © 2011 Kuete et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: VK received a six-month funding stay at the University of Mainz paid by the University of Mainz, and a three-month stay as DAAD fellow at the University of Mainz. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: efferth@uni-mainz.de

Introduction

Natural products are well recognized as sources for drugs in several human ailments including cancers. Examples of natural pharmaceuticals from plants include vincristine, irinotecan, etoposide and paclitaxel [1]. Despite the discovery of many drugs of natural origin, the search for new anticancer agents is still necessary, in order to increase the range available and to find less toxic and more effective drugs. It has been recommended that samples with pharmacological usage should be taken into account when selecting plants to treat cancer, as several ailments reflect disease states bearing relevance to cancer or cancer-like symptoms [2,3]. Therefore, we designed the present work to investigate the cytotoxicity of six natural compounds available in our research group, with previously demonstrated pharmacological activities. Compound 1 has been isolated from the roots of *Cratoxylum*

formosum [4], the leaves of *Symphonia globulifera* [5], and the seeds of *Vismia laurentii* [6]. The only reported natural source of compound 2 is *Newbouldia laevis* in which it can be isolated from the roots [7]. Compound 3 is a key active ingredient of the ethanol extract from roots of Chinese rhubarb (*Rheum officinale* Baill.) that has been commercialised in China for controlling powdery mildews [8]. Compound 3 was purified from several plants including *Rumex japonicus* [9], *Radix Boehmeriae* [10], *Discocleidion rufescens* [11], *Senna septemtrionalis* [12], etc. Compounds 4 and 5 are mostly found in plants of the genus *Vismia* [13,14], whilst compound 6 was reported in *Vimia laurentii* [13] and *Psorospermum* species [15]. Compounds 2; 4; 5 and 6 previously showed antimicrobial activities against a panel of bacteria and fungi [13,16]; compound 3 exhibited antibacterial activities against *Chlorella fusa* and *Bacillus megaterium*, respectively [6] and compound 1 showed antileishmanial [5] and cytotoxic activities against HeLa, HT-29 and KB cell

lines [4]. Compound **1** also exhibited significant antibacterial activities on *Pseudomonas aeruginosa*, *Bacillus cereus*, *Staphylococcus aureus*, *Streptococcus faecalis* and *Salmonella typhi* with minimal inhibitory concentration below 10 µg/ml [4]. In the present work, we examined at first, the cytotoxicity of compounds **1–6** against MiaPaCa-2, CCRF-CEM, and CEM/ADR5000 cell lines, then we selected compounds **1** and **2** which were tested on a panel of cancer cells. Their possible modes of action were also investigated and reported herein.

Results and Discussion

The six naturally occurring compounds tested included one xanthone named xanthone V₁ (**1**) and five quinones amongst which were three anthraquinones known as physcion (**3**); vismiaquinone (**5**) and 1,8-dihydroxy-3-geranyloxy-6-methylanthraquinone (**6**), one naphthoquinone known as 2-acetylfuro-1,4-naphthoquinone (**2**) and one binaphthoquinone named bisvismiaquinone (**4**) (Fig. 1). The four studied naphthoquinones have compound **3** as the basic moiety. The preliminary cytotoxicity of the six studied compounds on CCRF-CEM, CEM/ADR5000 and MiaPaca-2 is summarized in Fig. 2. Only xanthone V₁ and 2-acetylfuro-1,4-naphthoquinone as well as doxorubicin were able to reduce the proliferation of the three cell lines by up to 50%, when tested at 20 µg/ml. Physcion was previously found to have no cytotoxic activity on some cancer cell lines such as K562, HeLa, Calu-1, Wish and Raji [17] and was not significantly active as observed in the present work. However, the low activity of 8-dihydroxy-3-geranyloxy-6-methylanthraquinone (**6**), as well as bisvismiaquinone (**4**) and vismiaquinone (**5**) also bearing physcion (**3**) moiety, clearly highlights the low cytotoxicity of the studied anthraquinones. It can be deduced that the best cytotoxic activity of the studied compounds were obtained with the tested xanthone (xanthone V₁) and naphthoquinone (2-acetylfuro-1,4-naphthoquinone). Xanthone V₁ and 2-acetylfuro-1,4-naphthoquinone were therefore selected and tested on several cancer cells. The IC₅₀ values obtained are reported in Table 1 and values below 20 µg/ml were recorded on 12 of the 14 (85.71%) tested cancer cell lines for xanthone V₁ and 14/14 (100%) for 2-acetylfuro-1,4-naphthoquinone. Considering the cut-off points of 4 µg/ml [18] or 10 µM [19] for good cytotoxic compounds, values around or below this set point were obtained by xanthone V₁ on 9/14 (64.29%) tested cancer cell lines and 11/14 (78.57%) for 2-acetylfuro-1,4-naphthoquinone. The most sensitive cell lines (with IC₅₀ values below 1 µg/ml) were breast MCF-7 (to xanthone V₁) and cervix HeLa and Caski (to xanthone V₁ and 2-acetylfuro-1,4-naphthoquinone), leukemia PF-382 and melanoma colo-38 (to 2-acetylfuro-1,4-naphthoquinone). The liver is the main organ involved in drug metabolism. Therefore AML12 hepatocyte were chosen in the present work to evaluate the cytotoxicity of the compounds on non cancer cells. Interestingly, the two compounds were generally less toxic on AML12 cells, the IC₅₀ being above 20 µg/ml. In addition, the two compounds showed respectively, 65.8% and 59.6% inhibition of the growth of blood capillaries on the chorioallantoic membrane of quail eggs in the anti-angiogenic assay (Fig. 3), suggesting that negative effect on tumor promotion *in vivo* could be expected. To the best of our knowledge, the anticancer activity of 2-acetylfuro-1,4-naphthoquinone is being reported herein for the first time meanwhile the cytotoxicity of xanthone V₁ was reported on HeLa, HT-29 and KB cell lines [4]. This study thus confirms the cytotoxic potency of xanthone V₁ on a large number of cancer cell lines. The effects on xanthone V₁ and 2-acetylfuro-1,4-naphthoquinone on the cell cycle distribution, apoptosis induction (Figs. 4 and 5) and caspase

3/7 activity (Fig. 6) were investigated in CCRF-CEM cell line. Fig. 4 shows that xanthone V₁ was able to induce cell cycle arrest at higher concentration (2×IC₅₀). At 2×IC₅₀, the cell number in S-phase gradually increased (Fig. 4B1–3) with time upon treatment with xanthone V₁, and the highest amount was observed after 72 h, suggesting a cycle arrest at this phase. Up to 8.51% and 10.53% apoptotic cells were observed after 72 h upon treatment of CCRF-CEM cells with xanthone V₁ at IC₅₀ and 2×IC₅₀, respectively. This result is in accordance with the activation of caspases 3/7 (182.58% activation compare to untreated cells) (Fig. 6), though the effect at 2×IC₅₀ was less than that obtained at a concentration corresponding to IC₅₀ value (1231% activation). This is obviously due to the fact that, despite the activation of caspase induced by this compound, the ratio of cell number-activity might still be better at IC₅₀ than at 2×IC₅₀. Fig. 5 also shows that 2-acetylfuro-1,4-naphthoquinone induced cell cycle arrest in S-phase when tested at 2×IC₅₀ and IC₅₀ values in a time-dependant manner. This compound induced apoptosis, eventhough without caspase 3/7 activation (data not shown). This suggests that the activation of caspase might not be the main pathway for apoptosis induction by 2-acetylfuro-1,4-naphthoquinone.

The overall results of the present work highlight the anticancer potency of xanthone V₁ and 2-acetylfuro-1,4-naphthoquinone, and clearly justify the fact that all compounds with any pharmacological activity should also be evaluated for its cytotoxicity. The most sensitive cancer cell lines to xanthone V₁ and 2-acetylfuro-1,4-naphthoquinone were Colo-38 (melanoma), HeLa and Caski (cervix cancer) with IC₅₀ values being closer or lower those obtained with doxorubicin. In addition, MCF-7 (breast cancer) and PF-382 (leukemia) also showed high sensitivity to xanthone V₁ and 2-acetylfuro-1,4-naphthoquinone respectively. The cytotoxicity of acetylfuro-1,4-naphthoquinone is being reported for the first time. Regarding the medical impact of these cancers, the activities of these two molecules could be considered as very important. In fact, breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females worldwide, accounting for 23% of the total cancer cases and 14% of the cancer deaths, meanwhile cervix and colon cancers are also amongst the most common cancer in economically developing and developed world respectively [20].

In conclusion, the results of the present study provide evidence of the cytotoxicity of xanthone V₁ and 2-acetylfuro-1,4-naphthoquinone, and bring supportive data for future investigations that will lead to their use in cancer therapy.

Materials and Methods

Ethics Statement

Cell lines were obtained from different sources; Prof. Axel Sauerbrey, University of Jena, Jena, Germany: CCRF-CEM, CEM/ADR5000, HL-60; German Collection for Microorganisms and Cell Culture (DSMZ), Braunschweig, Germany: PF-382; Dr. Jörg Hoheisel, DKFZ, Heidelberg, Germany: MiaPaCa-2, Capan-1 pancreatic adenocarcinoma, MCF-7 breast adenocarcinoma, SW-680 colon carcinoma cells; Tumor Bank, German Cancer Research Center (DKFZ), Heidelberg, Germany: 786-0 renal carcinoma cells, U87MG glioblastoma-astrocytoma cells, A549 lung adenocarcinoma, Caski and HeLa cervical carcinoma cells, Colo-38 skin melanoma cells; ATCC, USA: AML12 hepatocytes.

Chemical for cytotoxicity assay

Doxorubicin (Sigma-Aldrich, Schnellendorf, Germany) was used as a positive (cytotoxic) control. The six natural compounds tested




Figure 1. Chemical structures of the studied compounds. **1:** xanthone V₁, **2:** 2-acetylfuro-1,4-naphthoquinone; **3:** physcion; **4:** bisvismiaquinone; **5:** vismiaquinone; **6:** 1,8-dihydroxy-3-geranyloxy-6-methylantraquinone. doi:10.1371/journal.pone.0021762.g001

in this study are available in our research group and their isolation as well as characterization were previously reported: xanthone V₁ C₂₃H₂₂O₆ (**1**; m/z 394; m.p. 214–215, yellow powder) and physcion C₁₆H₁₂O₅ (**3**; m/z 394; m.p. 202–205, orange solid) from the seeds of *Vismia laurentii* [6]; 2-acetylfuro-1,4-naphthoquinone C₁₄H₈O₄ (**2**; m/z: 242; m.p. 224–225; yellow powder) from the roots bark of *Newbouldia laevis* [21]; bisvismiaquinone C₁₂H₄₂O₈ (**4**; m/z: 674; m.p. 207–209; yellow powder), vismiaquinone C₂₁H₂₀O₅ (**5**; m/z: 352; m.p. 201–203; red powder), 1,8-dihydroxy-3-geranyloxy-6-methylantraquinone C₂₅H₂₆O₅ (**6**;

m/z: 406; m.p. 119–121; orange needle) from the twigs of *Vismia laurentii* [13]. The determination of each chemical structure was made as previously reported [6,21,13]. Generally they were determined on the basis of spectral data produced by one- and two-dimensional nuclear magnetic resonance (NMR), recorded on Brüker DRX-400 instrument. This spectrometer was equipped with 5 mm, ¹H and ¹³C NMR probes operating at 400 and 100 MHz, with tetramethylsilane as internal standard. Mass spectra were recorded on an API QSTAR pulsar mass spectrometer. All chemicals were stored at 4°C before use.




Figure 2. Growth percentage (%) of compounds and doxorubicin tested at 20 µg/ml on CCRF-CEM, CEM/ADR5000 and MiaPaCa-2 cell lines. **1:** xanthone V₁, **2:** 2-acetylfuro-1,4-naphthoquinone; **3:** physcion; **4:** bisvismiaquinone; **5:** vismiaquinone; **6:** 1,8-dihydroxy-3-geranyloxy-6-methylantraquinone. Data with different superscript letters are significantly different (P<0.05). doi:10.1371/journal.pone.0021762.g002

Table 1. Cytotoxicity of compounds **1**, **2** and doxorubicin on different cancer cell lines.

Cell lines	Samples and IC ₅₀ values					
	1		2		Doxorubicin	
	µg/ml	µM	µg/ml	µM	µg/ml	µM
CCRF-CEM	4.90±0.71	12.44±1.80	9.41±2.79	35.88±11.53	1.24±0.003	1.28±0.005
CEM/ADR5000	19.06±2.21	48.07±5.61	16.75±0.42	69.21±1.74	>20	>36.8
PF-382	>20	>50.76	0.57±0.06	2.36±0.25	1.90±0.037	3.50±0.007
HL-60	4.56±0.57	11.57±1.42	4.81±0.77	19.88±3.18	1.57±0.11	2.89±0.20
MiaPaCa-2	18.56±1.76	47.11±4.47	1.81±0.02	7.48±0.08	0.95±0.06	1.75±0.11
Capan-1	>20	>50.76	3.81±0.96	15.74±3.97	4.06±1.18	7.47±2.17
MCF-7	0.56±0.06	1.42±0.15	1.66±0.09	6.86±0.72	0.59±0.05	1.08±0.09
SW-680	8.40±0.45	21.32±1.14	3.55±0.02	14.67±0.08	0.93±0.09	1.71±0.17
786-0	3.79±0.16	9.62±0.41	6.81±0.61	28.14±2.52	0.60±0.09	1.10±0.17
U87MG	3.80±0.01	9.64±0.03	1.94±0.18	8.02±0.74	0.37±0.08	0.68±0.14
A549	3.99±0.09	10.13±0.23	5.49±0.35	22.69±1.44	1.69±0.05	3.11±0.09
Colo-38	1.19±0.07	3.02±1.78	0.67±0.18	2.77±0.74	0.81±0.06	1.49±0.11
HeLa	0.23±0.01	0.58±0.03	0.40±0.10	1.65±0.41	0.26±0.02	0.48±0.04
Caski	0.24±0.01	0.61±0.03	0.17±0.03	0.70±0.12	0.58±0.02	1.07±0.04
AML12 (EC ₅₀)*	>20	>50.76	>20	>82.64	>20	>36.8

*EC₅₀: effective dose showing 50% inhibition of growth proliferation.

doi:10.1371/journal.pone.0021762.t001

Cell lines and treatment

A panel of fourteen cancer cell lines including human CCRF-CEM leukemia cells and their multidrug-resistant subline, CEM/ADR5000, PF-382 leukemia T-cells, and HL-60 promyelocytic leukemia (moderately differentiated), MiaPaCa-2 and Capan-1 pancreatic adenocarcinoma, MCF-7 breast adenocarcinoma, SW-680 colon carcinoma cells, 786-0 renal carcinoma cells, U87MG glioblastoma-astrocytoma cells, A549 lung adenocarcinoma, Caski and HeLa cervical carcinoma cells, Colo-38 skin melanoma cells, as well as AML12 hepatocytes (poorly differentiated), were used. CCRF-CEM, CEM/ADR5000 and MiaPaCa-2 cells were used for the preliminary assay and the most active compounds were tested on other cell lines. Leukemia cells were maintained in RPMI 1640 containing 100 units/ml penicillin and 100 µg/ml streptomycin and supplemented with heat-inactivated 10% fetal bovine serum (FBS). All cultured cells were maintained in a humidified environment at 37°C with 5% CO₂. Doxorubicin

(Sigma-Aldrich, Schnellendorf, Germany) was used as a positive (cytotoxic) control. The concentration of DMSO was not greater than 0.1% in all experiments.

Resazurin cell growth inhibition assay

Alamar Blue or Resazurin (Promega, Mannheim, Germany) reduction assay [22] was used to assess the cytotoxicity of the studied samples. The assay tests cellular viability and mitochondrial function. Briefly, adherent cells were grown in tissue culture flasks, and then harvested by treating the flasks with 0.025% trypsin and 0.25 mM EDTA for 5 min. Once detached, cells were washed, counted and an aliquot (5×10^3 cells) was placed in each well of a 96-well cell culture plate in a total volume of 100 µl. Cells were allowed to attach overnight and then treated with samples. The final concentration of samples ranged from 20-0.16 µg/ml. After 48 h, 20 µl resazurin 0.01% w/v solution was added to each well and the plates were incubated at 37°C for 1–2 h.




Figure 3. Effects of compound 1 and 2 (at 20 µg/ml) on the growth of blood capillaries on the chorioallantoic membrane of quail eggs. (A) DMSO (Control): growth of blood capillaries on the CAM – no antiangiogenic effect; (B): compound **1** (65.8% inhibition); (C): compound **2** (59.6% inhibition). Quantitative analysis was performed using a software routine which was written in the Image J-macro language, and the total small vessels number was then determined by the system as 44644 (control), 15273 (compound **1**) and 18050 (compound **2**). The inhibition percentage was then calculated as previously described [27].

doi:10.1371/journal.pone.0021762.g003




Figure 4. Cell cycle distribution with Leukemia CCRF-CEM treated with compounds 1. A1: control after 24 h; A2: control after 48 h; A3: control after 72 h; B1: treated with 2×IC₅₀ after 24 h; B2: treated with 2×IC₅₀ after 48 h; B3: treated with 2×IC₅₀ after 72 h; C1: treated with 2×IC₅₀ after 24 h; C2: treated with 2×IC₅₀ after 48 h; C3: treated with 2×IC₅₀ after 72 h; D1: treated with 2×IC₅₀ after 24 h; D2: treated with 2×IC₅₀ after 48 h; D3: treated with 2×IC₅₀ after 72 h. doi:10.1371/journal.pone.0021762.g004

Fluorescence was measured on an automated 96-well Infinite M2000 Pro™ plate reader (Tecan, Crailsheim, Germany) using an excitation wavelength of 544 nm and an emission wavelength of 590 nm. For leukemia cells, aliquot of 5×10^4 cells/ml (obtained from overnight suspension) were seeded in 96-well plates, and extracts were added immediately. After 24 h incubation, plates were treated with resazurin solution as above mentioned. Doxorubicin was used as positive control. Each assay was done at least three times, with two replicates each. The viability was compared based on a comparison with untreated cells. IC₅₀ (on cancer cells) or EC₅₀ (on AML12 cells) values were the concentration of sample required to inhibit 50% of the cell proliferation and were calculated from a calibration curve by a linear regression [23] using Microsoft Excel.

Flow cytometry for cell cycle analysis and detection of apoptotic cells

Leukemia CCRF-CEM cells treated with compounds 1 and 2 or DMSO (solvent control) for 24 to 72 h were fixed with ethanol 95% and washed with cold, phosphate-buffered saline (PBS; Invitrogen) and then resuspended in 150 μl hypotonic fluorochrome solution (50 μg/ml propidium iodide, 0.1% (w/v) sodium citrate and 0.1% (v/v) Triton X-100). The cells were incubated in the dark at 4°C overnight before flow-cytometry analysis was performed. The propidium iodide fluorescence of individual nuclei was measured using a FACS-Calibur cytometer (BD Biosciences,

Heidelberg, Germany). Data were analyzed with the CellQuest Pro V5.2.1 software (BD Biosciences). For each condition, at least three independent experiments were performed.

Caspase-Glo 3/7 assay

The influence of compounds 1 and 2 on caspase 3/7 activity in CCRF-CEM leukemia cell line was detected using Caspase-Glo 3/7 Assay kit (Promega). Cells cultured in RPMI were seeded in 96-well plates and treated with the sample (2×IC₅₀; IC₅₀; ½ IC₅₀) or DMSO (solvent control). After 24 h treatment, 100 μl of caspase 3/7 reagent were added to each well, mixed and incubated for 1 h at room temperature. Luminescence was measured using well Infinite M2000 Pro™ instrument (Tecan). Caspase 3/7 activity was expressed as percentage of the untreated control.

Angiogenesis test

Cultivation of quail eggs. The quail eggs were purchased from Wachtelzucht Anne Klein, Steinhagen, Germany.

The embryos were cultured according to the method described by Wittmann et al. [24]. Briefly, fertilized quail eggs were incubated for 70 h at 38°C and 80% relative humidity. After 70 h of incubation the eggs were opened. For this purpose, the eggs were placed in a vertical position to guarantee that the embryo floats in the upper part of the egg. Afterwards, hole was cut in to the top of the egg and the complete content of the egg was transferred into a Petri dish. By using this method, it could be




Figure 5. Cell cycle distribution with Leukemia CCRF-CEM treated with compounds 2. A1: control after 24 h; A2: control after 48 h; A3: control after 72 h; B1: treated with 2xIC₅₀ after 24 h; B2: treated with 2xIC₅₀ after 48 h; B3: treated with 2xIC₅₀ after 72 h; C1: treated with 2xIC₅₀ after 24 h; C2: treated with 2xIC₅₀ after 48 h; C3: treated with 2xIC₅₀ after 72 h; D1: treated with 2xIC₅₀ after 24 h; D2: treated with 2xIC₅₀ after 48 h; D3: treated with 2xIC₅₀ after 72 h. doi:10.1371/journal.pone.0021762.g005

guaranteed that the albumin gets first into the Petri dish followed by the yolk with the embryo on top without exposing the embryo to shock-forces which could damage the vitelline membrane.

Chicken-Chorioallantoic-membran-Assay (CAM-Assay)

Compounds 1 and 2 were tested for their anti-angiogenic effects using the method of D'Arcy and Howard [25], with modifications




Figure 6. Enzymatic activity of caspase 3/7 after 6 h treatment of CCRF-CEM cells with compounds 1. The activity of caspase 3/7 is expressed as percentage % relative to untreated cells. Compound 2 did not show any induction of caspase 3/7 activity (data not shown). Values are mean ± SD of three duplicated experiments. doi:10.1371/journal.pone.0021762.g006

according to Marchesan et al. [26]. Briefly, the explanted embryo was placed in an incubator for 2 h at 38°C to acclimatize to the new ambience. Subsequently, the test substance was placed on the chorioallantoic membrane (CAM). Therefore, 2% agarose solution was prepared and mixed 1:10 with compounds prior diluted in DMSO 0.1% final concentration. The final concentration of the substance was 20 µg/ml. Pellets with 0.1% DMSO served as control. The agarose-pellets were then placed on the chorioallantoic membrane after they cooled down to room temperature. The Petri dishes with the quail embryos were placed in the incubator again and incubated at 38°C and 80% relative humidity for 24 h before documenting the effect of the applied substance.

Imaging of the vascularized quail eggs was performed using a digital camera with 3×-magnification objective (Canon eos 500 with a canon mp-e 65 2.8 macro objective). For illumination, a mercury-arc-lamp was used which provided a high fraction of blue and UV-light to obtain good contrast values between yolk and vessels. The pictured image section had a size of 5×5 mm. Following image acquisition, quantitative analysis was performed using a software routine which was written in the Image J-macro language, and the total small vessels number (or area) was then

determined by the system. The percentage inhibition of vascularization was calculated as previously described [27].

Statistical analysis

Statistical analysis of all data was performed using a Student's *t*-test or Kruskal–Wallis test followed by Dunn's post-hoc multiple comparison test (Graph-Pad Prism 5.01; GraphPad Software, Inc., CA, USA). $P < 0.05$ denoted significance in all cases.

Acknowledgments

Authors are thankful to the National Herbarium of Cameroon (Yaounde) and Mr. Paul Lungu (University of Dschang) for their technical support and language editing. VK is also very grateful to the Department of Pharmaceutical Biology, Johannes-Gutenberg University, Mainz, Germany.

Author Contributions

Conceived and designed the experiments: VK HKW KOE MFT BW GF PT TE. Performed the experiments: VK MFT BK. Analyzed the data: VK. Contributed reagents/materials/analysis tools: VK HKW KOE MFT TE. Wrote the paper: VK TE.

References

- Da Rocha BA, Lopes RM, Schwartzmann G (2001) Natural products in anticancer therapy. *Curr Opin Pharmacol* 1: 364–369.
- Cordell GA, Beccher CW, Pezzuto JM (1991) Can ethnopharmacology contribute to development of new anti-cancer? *J Ethnopharmacol* 32: 117–133.
- Popoca J, Aguilar A, Alonso D, Villarreal ML (1998) Cytotoxic activity of selected plants used as antitumorals in Mexican traditional medicine. *J Ethnopharmacol* 59: 173–177.
- Boonsri S, Karalai C, Ponglimanont C, Kanjana-Opas A, Chantrapromma K (2006) Antibacterial and cytotoxic xanthenes from the roots of *Cratogeomys formosum*. *Phytochemistry* 67: 723–727.
- Lenta DJ, Vonthron-Sénécheau C, Weniger B, Devkota KP, Ngoupayo J, et al. (2007) Leishmanicidal and cholinesterase inhibiting activities of phenolic compounds from *Allanblackia monticola* and *Symphonia globulifera*. *Molecules* 12: 1548–1557.
- Wabo HK, Kouam SF, Krohn K, Hussain H, Tala MF, et al. (2007) Prenylated anthraquinones and other constituents from the seeds of *Vismia laurentii*. *Chem Pharm Bull (Tokyo)* 55: 1640–1642.
- Eyong KO, Krohn K, Hussain H, Folefoc GN, Nkengfack AE, et al. (2005) Newbouldiaquinone and newbouldiamide: a new naphthoquinone-anthraquinone coupled pigment and a new ceramide from *Newbouldia laevis*. *Chem Pharm Bull (Tokyo)* 53: 616–619.
- Ma X, Yang X, Zeng F, Yang L, Yu D, et al. (2010) Physcion, a natural anthraquinone derivative, enhances the gene expression of leaf-specific thionin of barley against *Blumeria graminis*. *Pest Manag Sci* 66: 718–724.
- Guo S, Feng B, Zhu R, Ma J, Wang W (2011) Preparative isolation of three anthraquinones from *Rumex japonicus* by high-speed counter-current chromatography. *Molecules* 16: 1201–1210.
- Shao LJ, Wang JN (2010) Studies on the chemical constituents of *Radix boehmeriae*. *Zhong Yao Cai* 33: 1091–1093.
- Wang J, Zhang Y, Chen S, Zhao M, Zhang L (2010) Chemical constituents of *Discocleidia rufescens*. *Zhongguo Zhong Yao Za Zhi* 35: 1435–1438.
- Alemayehu G, Adane L, Abegaz BM (2010) A new bianthracene C-arabinopyranoside from *Senna septemtrionalis*. *Nat Prod Commun* 5: 747–750.
- Kuete V, Nguemaving JR, Beng VP, Azebaze AG, Etoa FX, et al. (2007) Antimicrobial activity of the methanolic extracts and compounds from *Vismia laurentii* De Wild (Guttiferaceae). *J Ethnopharmacol* 109: 372–379.
- Hussein AA, Bozzi B, Correa M, Capson TL, Kursar TA, et al. (2003) Bioactive constituents from three *Vismia* species. *J Nat Prod* 66: 858–860.
- Tsaffack M, Nguemaving JR, Kuete V, Ndejouong Tchize Ble S, Mkounga P, et al. (2009) Two new antimicrobial dimeric compounds: febrifluquinone, a vismione-anthraquinone coupled pigment and adamabianthrone, from two *Psorospermum* species. *Chem Pharm Bull (Tokyo)* 57: 1113–1118.
- Kuete V, Eyong KO, Folefoc GN, Beng VP, Hussain H, et al. (2007) Antimicrobial activity of the methanolic extract and of the chemical constituents isolated from *Newbouldia laevis*. *Pharmazie* 62: 552–556.
- Kuo Y-C, Sun M-C, Ou J-C, Tsai W-J (1997) A tumor cell growth inhibitor from *Polygonum hypoleucum* Ohwi. *Life Sciences* 61: 2335–2344.
- Boik J (2001) *Natural Compounds in Cancer Therapy*. Princeton: Oregon Medical Press.
- Brahemi G, Kona FR, Fiasella A, Buac D, Soukupov J, et al. (2010) Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer. *J Med Chem* 53: 2757–2765.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. *CA Cancer J Clin*. doi:10.3322/caac.20107.
- Eyong KO, Folefoc GN, Kuete V, Beng VP, Krohn K, et al. (2006) Newbouldiaquinone A: A naphthoquinone-anthraquinone ether coupled pigment, as a potential antimicrobial and antimalarial agent from *Newbouldia laevis*. *Phytochemistry* 67: 605–609.
- O'Brien J, Wilson I, Orton T, Pognan F (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. *Eur J Biochem* 267: 5421–5426.
- Joshi SC, Verma AR, Mathela CS (2010) Antioxidant and antibacterial activities of the leaf essential oils of Himalayan Lauraceae species. *Food Chem Toxicol* 48: 37–40.
- Wittmann J, Kugler W, Kaltner H (1987) Cultivation of the early quail embryo: induction of embryogenesis under in vitro conditions. *J Exp Zool Suppl* 1: 325–328.
- D'Arcy PF, Howard EM (1967) A new anti-inflammatory test, utilizing the chorioallantoic membrane of the chick embryo. *Br J Pharmacol Chemother* 29: 378–387.
- Marchesan M, Paper DH, Hose S, Franz G (1998) Investigations of the anti-inflammatory activity of liquid extracts of *Plantago lanceolata* L. *Phytother Res* 12: S33–S34.
- Kuete V, Youns M, Krusche B, Voukeng I, Fankam AG, et al. (2011) Anticancer activities of some Cameroonian species and selected medicinal plant extracts. *J Ethnopharmacol* doi:10.1016/j.jep.2011.01.035.